Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials

MT Newswires Live12-19

Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse.

Benmelstobart Injection is sometimes used with Anlotinib Capsules for treating a specific type of lung cancer (Stage III non-small cell lung cancer) that cannot be removed or has advanced locally.

The interim analysis of the drug shows "primary study endpoint progression-free survival (PFS) has met the protocol's predefined superiority threshold."

The pharmaceutical has contacted China's Centre for Drug Evaluation about submitting a marketing application.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492683149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492683149","market":"hk","top_or_hot":-1,"title":"Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials","media":"MT Newswires Live","content":"<html><body><p> Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse.</p><p>Benmelstobart Injection is sometimes used with Anlotinib Capsules for treating a specific type of lung cancer (Stage III non-small cell lung cancer) that cannot be removed or has advanced locally.</p><p>The interim analysis of the drug shows \"primary study endpoint progression-free survival (PFS) has met the protocol's predefined superiority threshold.\"</p><p>The pharmaceutical has contacted China's Centre for Drug Evaluation about submitting a marketing application.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 17:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492683149","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492683149","pubTimestamp":1734599330,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse.Benmelst","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK1589":"北水核心资产","BK4211":"区域性银行","01177":"中国生物制药","PFS":"Provident Financial Services Inc","BK4195":"互助储蓄与抵押信贷金融服务","BK1191":"制药"},"translate_title":"中国生物制药抗癌药物临床试验显示积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"01177":0.9},"content_text":"Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse.Benmelstobart Injection is sometimes used with Anlotinib Capsules for treating a specific type of lung cancer (Stage III non-small cell lung cancer) that cannot be removed or has advanced locally.The interim analysis of the drug shows \"primary study endpoint progression-free survival (PFS) has met the protocol's predefined superiority threshold.\"The pharmaceutical has contacted China's Centre for Drug Evaluation about submitting a marketing application.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492683149"}